BioSpace News Archive

Medpace Holdings, Inc. announced financial results for the third quarter ended September 30, 2022.

Denali Therapeutics Inc. announced the closing of its upsized underwritten public offering of 11,933,962 shares of its common stock at a price to the public of $26.50 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares.

Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022.

Cingulate Inc. announced it has executed a Master Services Agreement with Societal CDMO, Inc., a bi-coastal contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.

Sauvie Inc. announced Sauvie’s subsidiary, Sauvie BiKE LLC, has entered into an exclusive license agreement with Rutgers, The State University of New Jersey for the development and worldwide commercialization rights of a bi-specific natural killer cell engager technology in the field of oncology.

Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announced key organizational and financial updates.

Palatin Technologies, Inc. (NYSE American: PTN) today announced that John Dodd, Ph.D. presented the poster “Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal Inflammatory Diseases” at the American College of Gastroenterology annual meeting in Charlotte, North Carolina.

Astellas Pharma Inc. and Taysha Gene Therapies, Inc. announced a strategic investment to support the advancement of Taysha’s adeno-associated virus gene therapy development programs for the treatment of Rett syndrome and GAN.

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce it presented results from a proof of concept study at the International Society of Liquid Biopsy meeting in Miami, Florida on 20-22 October 2022.

Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced the appointment of Jens Würthner, MD, PhD, as Chief Medical Officer.